Canon Medical Systems USA has secured 510(k) clearance from the US Food and Drug Administration (FDA) for the Aquilion ONE / PRISM Edition, which allows Deep Learning Spectral capabilities for more routine spectral imaging.

The advanced system, designed for deep intelligence, integrates artificial intelligence (AI) technology to enhance conventional and spectral capabilities with automated workflows.

Furthermore, it assists physicians by providing deep clinical insights that enable more informed decision-making across the patient’s care cycle.

Aquilion ONE / PRISM Edition has Advanced intelligent Clear-IQ Engine (AiCE) that uses deep learning to identify the signal from noise to deliver precise images at rapid speeds.

AiCE, trained in using large amounts of high-quality image data, offers improved anatomical resolution across the whole body, including brain, cardiac, lung and musculoskeletal applications.

By enabling Deep Learning Spectral reconstruction, the Aquilion ONE / PRISM Edition aids healthcare providers to make confident diagnoses with spectral benefits of quick kV switching with patient-specific mA modulation, a complete field of view acquisition and 16cm of coverage.

Additionally, the completely integrated end-to-end workflow is seamless and added into routine protocols.

Canon Medical Systems USA CT business unit managing director said Erin Angel said: “Canon Medical’s DLR technology is pushing routine diagnostic imaging into the age of AI-assisted imaging, revolutionising patient care by enabling excellent diagnostic confidence.

“With Deep Learning Spectral, Canon Medical is able to provide clinicians with a spectral CT system designed to address the trade-offs of traditional spectral CT and potentially expanding the utilisation to more routine CT imaging.”

Headquartered in California, Canon Medical System USA sells and services radiology and cardiovascular systems.